Pfizer has presented data showing that its investigational, dual-mechanism poly ADP ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive (gBRCA+) advanced breast cancer … more

In the lung cancer space, Pfizer’s dacomitinib has slowly emerged as a contender, and becoming the first second-generation kinase inhibitor to report Phase 3 data should improve its profile … more